Abstract
Chronic lymphocytic leukemia (CLL) cells from clinically aggressive cases have a greater capacity to respond to external microenvironmental stimuli, including those transduced through Toll-like-receptor-9 (TLR9). Concomitant microRNA and gene expression profiling in purified CLL cells (n=17) expressing either unmutated (UM) or mutated (M) IGHV genes selected microRNAs from the miR-17∼92 family as significantly upregulated and in part responsible for modifications in the gene expression profile of UM CLL cells stimulated with the TLR9 agonist CpG. Notably, the stable and sustained upregulation of miR-17∼92 microRNAs by CpG was preceded by a transient induction of the proto-oncogene MYC. The enforced expression of miR-17, a major member from this family, reduced the expression of the tumor suppressor genes E2F5, TP53INP1, TRIM8 and ZBTB4, and protected cells from serum-free-induced apoptosis (P⩽0.05). Consistently, transfection with miR-17∼92 family antagomiRs reduced Bromo-deoxy-uridine incorporation in CpG-stimulated UM CLL cells. Finally, miR-17 expression levels, evaluated in 83 CLL samples, were significantly higher in UM (P=0.03) and ZAP-70high (P=0.02) cases. Altogether, these data reveal a role for microRNAs of the miR-17∼92 family in regulating pro-survival and growth-promoting responses of CLL cells to TLR9 triggering. Overall, targeting of this pathway may represent a novel therapeutic option for management of aggressive CLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Chiorazzi N, Rai KR, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815.
Borche L, Lim A, Binet JL, Dighiero G . Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990; 76: 562–569.
Sthoeger ZM, Wakai M, Tse DB, Vinciguerra VP, Allen SL, Budman DR et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989; 169: 255–268.
Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 2011; 25: 828–837.
Palacios F, Moreno P, Morande P, Abreu C, Correa A, Porro V et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood 2010; 115: 4488–4496.
Barton GM, Kagan JC . A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009; 9: 535–542.
Clark MR, Tanaka A, Powers SE, Veselits M . Receptors, subcellular compartments and the regulation of peripheral B cell responses: the illuminating state of anergy. Mol Immunol 2011; 48: 1281–1286.
Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P et al. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 2007; 21: 110–120.
Tarnani M, Laurenti L, Longo PG, Piccirillo N, Gobessi S, Mannocci A et al. The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia. Leuk Res 2010; 34: 1189–1194.
Lewis BP, Burge CB, Bartel DP . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.
Mattick JS . The genetic signatures of noncoding RNAs. PLoS Genet 2009; 5: e1000459.
Calin GA, Ferracin M, Cimmino A, Di LG, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793–1801.
Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113: 3801–3808.
Bomben R, Dal-Bo M, Benedetti D, Capello D, Forconi F, Marconi D et al. Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. Clin Cancer Res 2010; 16: 620–628.
Gattei V, Bulian P, Del Principe MI, Zucchetto A, Maurillo L, Buccisano F et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111: 865–873.
Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000; 28: 558–568.
Eisen MB, Spellman PT, Brown PO, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868.
Draghici S, Khatri P, Martins RP, Ostermeier GC, Krawetz SA . Global functional profiling of gene expression. Genomics 2003; 81: 98–104.
Volinia S, Visone R, Galasso M, Rossi E, Croce CM . Identification of microRNA activity by Targets’ Reverse EXpression. Bioinformatics 2010; 26: 91–97.
Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010; 29: 5071–5082.
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008; 132: 875–886.
Lee Y, Jeon K, Lee JT, Kim S, Kim VN . MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21: 4663–4670.
Okumura F, Matsunaga Y, Katayama Y, Nakayama KI, Hatakeyama S . TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J Cell Sci 2010; 123: 2238–2245.
Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM et al. E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control. Mol Cell 2000; 6: 729–735.
Weber A, Marquardt J, Elzi D, Forster N, Starke S, Glaum A et al. Zbtb4 represses transcription of P21CIP1 and controls the cellular response to p53 activation. EMBO J 2008; 27: 1563–1574.
Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell 2001; 8: 85–94.
Chi SW, Zang JB, Mele A, Darnell RB . Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009; 460: 479–486.
Emmrich S, Putzer BM . Checks and balances: E2F-microRNA crosstalk in cancer control. Cell Cycle 2010; 9: 2555–2567.
Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA et al. Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene 2012; 31: 1034–1044.
Kurisetty V, Kovacs K, Luongo T, Erchan J . hsa-miR-20a promotes tumorigenesis in ccRCC cancer cell lines [abstract]. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research 2011, Orlando, FL, USA.
Tan LP, Seinen E, Duns G, de JD, Sibon OC, Poppema S et al. A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res 2009; 37: e137.
Trompeter HI, Abbad H, Iwaniuk KM, Hafner M, Renwick N, Tuschl T et al. MicroRNAs mir-17, mir-20a, and mir-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One 2011; 6: e16138.
Wang Q, Li YC, Wang J, Kong J, Qi Y, Quigg RJ et al. miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci USA 2008; 105: 2889–2894.
Yeung ML, Yasunaga J, Bennasser Y, Dusetti N, Harris D, Ahmad N et al. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res 2008; 68: 8976–8985.
Li C, Kim SW, Rai D, Bolla AR, Adhvaryu S, Kinney MC et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood 2009; 113: 6681–6690.
Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43–50.
O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839–843.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828–833.
Onnis A, De FG, Antonicelli G, Onorati M, Bellan C, Sherman O et al. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 2010; 5: pii: e12960.
Tomic J, Lichty B, Spaner DE . Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood 2011; 117: 2668–2680.
Plander M, Seegers S, Ugocsai P, Ermeier-Daucher S, Ivanyi J, Schmitz G et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009; 23: 2118–2128.
Bernasconi NL, Onai N, Lanzavecchia A . A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003; 101: 4500–4504.
Jahrsdorfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005; 77: 378–387.
Cloonan N, Brown MK, Steptoe AL, Wani S, Chan WL, Forrest AR et al. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol 2008; 9: R127.
Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007; 109: 4399–4405.
Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628–9632.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257–2261.
Fujimoto M, Naka T . SOCS1, a negative regulator of cytokine signals and TLR responses, in human liver diseases. Gastroenterol Res Pract 2010; 2010: pii: 470468.
Cui JW, Li YJ, Sarkar A, Brown J, Tan YH, Premyslova M et al. Retroviral insertional activation of the Fli-3 locus in erythroleukemias encoding a cluster of microRNAs that convert Epo-induced differentiation to proliferation. Blood 2007; 110: 2631–2640.
Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfo L, Rossi C et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010; 115: 3949–3959.
Allsup DJ, Kamiguti AS, Lin K, Sherrington PD, Matrai Z, Slupsky JR et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 2005; 65: 7328–7337.
Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036–2041.
Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG . ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007; 109: 2032–2039.
Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK . Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007; 109: 4424–4431.
Albihn A, Johnsen JI, Henriksson MA . MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010; 107: 163–224.
Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J et al. ERK activation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med 2010; 16: 665–670.
Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475: 101–105.
Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008; 14: 665–674.
Rosen A, Murray F, Evaldsson C, Rosenquist R . Antigens in chronic lymphocytic leukemia—implications for cell origin and leukemogenesis. Semin Cancer Biol 2010; 20: 400–409.
Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563–574.
Acknowledgements
This work was supported in part by: Ministero della Salute, Ricerca Finalizzata I.R.C.C.S., ‘Alleanza Contro il Cancro’; Rete Nazionale Bio-Informatica Oncologica/RN-BIO; Progetto Giovani Ricercatori n. GR-2009-1475467, Rome, Italy; Progetto Giovani Ricercatori n. GR-2008-1138053, Rome, Italy; Fondazione Internazionale di Ricerca in Medicina Sperimentale (FIRMS); Associazione Italiana contro le Leucemie, linfomi e mielomi (AIL), Venezia Section, Pramaggiore Group, Italy; Ricerca Scientifica Applicata, Regione Friuli Venezia Giulia (‘Linfonet’ Project), Trieste, Italy; the Associazione Italiana Ricerca Cancro (AIRC, Investigator Grant IG-8701, IG-5917 and MFAG-10327), Milan, Italy; ‘5 × 1000 Intramural Program’, Centro di Riferimento Oncologico, Aviano, Italy; and The Leukemia & Lymphoma Society (grant no. R6170-10), White Plains, NY.
Author contributions
RB performed the research and wrote the manuscript; SG and MDB performed the research and contributed to the writing of the manuscript; ET, AZ and DB performed the research; SV and DM analyzed the miRNA and gene expression data; DR, GDP, GG and LL provided patients’ data; and DGE and VG designed the study and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Bomben, R., Gobessi, S., Dal Bo, M. et al. The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia 26, 1584–1593 (2012). https://doi.org/10.1038/leu.2012.44
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2012.44
Keywords
This article is cited by
-
Prognostic significance of microRNA 17–92 cluster expression in Egyptian chronic lymphocytic leukemia patients
Journal of the Egyptian National Cancer Institute (2021)
-
Identification of MiR-211-5p as a tumor suppressor by targeting ACSL4 in Hepatocellular Carcinoma
Journal of Translational Medicine (2020)
-
TRIM50 suppressed hepatocarcinoma progression through directly targeting SNAIL for ubiquitous degradation
Cell Death & Disease (2018)
-
TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours
Molecular Cancer (2017)
-
Proof-of-concept study: profile of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection
Virology Journal (2017)